title: Five cancer drugs back on NHS list after deals with drug companies.
authors.affiliation: London.
authors.forename: Nigel
authors.initials: N
authors.lastname: Hawkes
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000814:Aniline Compounds / Q000191:economics; D000970:Antineoplastic Agents / Q000191:economics / Q000600:supply & distribution*; D000068258:Bevacizumab / Q000191:economics; D000079963:Brentuximab Vedotin; D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D006801:Humans; D018796:Immunoconjugates / Q000191:economics; D009369:Neoplasms / Q000188:drug therapy*; D009570:Nitriles / Q000191:economics; D010880:Piperidines; D011720:Pyrazoles / Q000191:economics; D011743:Pyrimidines / Q000191:economics; D011804:Quinolines / Q000191:economics; D013222:State Medicine / Q000191:economics / Q000458:organization & administration*; D000068878:Trastuzumab / Q000191:economics; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D009570:Nitriles; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; D011804:Quinolines; C551803:ibrutinib; D000068258:Bevacizumab; C471992:bosutinib; D000079963:Brentuximab Vedotin; D000225:Adenine; D000068878:Trastuzumab